The Trump administration attempted to persuade a German science firm with “large sums of money” to leave Europe and develop a coronavirus vaccine “only for the United States,” according to reporting in a German newspaper Sunday.

The basics: CureVac, a German biopharmaceutical company, is developing an experimental vaccine for the coronavirus that it hopes to have by June or July, when it would then push for approval on human testing. Earlier this month, Trump, Vice President Mike Pence, and administration and industry leaders met with CureVac’s CEO, Daniel Menichella, to discuss the vaccine. (Menichella was replaced as CureVac CEO by the company’s founder on March 11.) Die Welt then reported that the United States reached out to broker an exclusive deal on the vaccine, prompting the German government to try to counter.

For its part, CureVac issued a statement on Sunday, saying, “The company rejects current rumors of an acquisition.”

But a spokesperson for the health ministry of Germany confirmed to Reuters there is an ongoing battle.